Certara was formed by the acquisition of Tripos®, Pharsight®, Simcyp, and Synchrogenix, each with a primary focus on a key phase within the drug discovery and development cycle, to create a single company with a unique set of capabilities for modeling, analysis, and simulation that span early discovery through Phase IV clinical trials.
Today, we are the global leader in biosimulation. Our quantitative science approach and unique portfolio of software and services that span the entire lifecycle accelerate medicines to patients, in concert with you.
For more information please visit: http://www.certara.com/